![Kyri van Hoose](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kyri van Hoose
Finanzdirektor/CFO bei
DERMATA THERAPEUTICS, INC.
Vermögen: 299 877 $ am 31.08.2026
Profil
Kyri K.
van Hoose is Vice President-Accounting at Turning Point Therapeutics, Inc. since 2021.
Mr. van Hoose is Chief Financial Officer & Senior Vice President at Dermata Therapeutics, Inc. since 2021.
Former roles include Corporate Controller & Senior Director-Finance at ACADIA Pharmaceuticals, Inc. from 2005 to 2016, Head-Finance at Avelas Biosciences, Inc. from 2017 to 2019, Head-Finance at Curzion Pharmaceuticals, Inc. from 2019 to 2020, and Chief Financial Officer at TEGA Therapeutics, Inc. from 2020 to 2021.
Education includes an undergraduate degree from the University of Southern California in 2000 and an MBA from the University of California, Irvine in 2005.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.08.2026 | 232’463 ( 8.2% ) | 299 877 $ | 31.08.2026 |
Aktive Positionen von Kyri van Hoose
| Unternehmen | Position | Beginn |
|---|---|---|
| TURG POIN | Comptroller/Controller/Auditor | 05.05.2021 |
| DERMATA THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.09.2021 |
Ehemalige bekannte Positionen von Kyri van Hoose
| Unternehmen | Position | Ende |
|---|---|---|
TEGA Therapeutics, Inc.
 TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics | Finanzdirektor/CFO | 30.04.2021 |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01.04.2020 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Finanzdirektor/CFO | 01.07.2019 |
| ACADIA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | 01.02.2016 |
Ausbildung von Kyri van Hoose
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
89
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
Dermata Therapeutics, Inc.
 Dermata Therapeutics, Inc. Household/Personal CareConsumer Non-Durables Develops direct-to-consumer skincare products | Consumer Non-Durables |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Develops integrated suite of therapeutic and imaging agents for treatment of cancer | Health Services |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
TEGA Therapeutics, Inc.
TEGA Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics | Health Technology |
